相关实验视频
Updated: Sep 16, 2025

09:36
Isolated Pancreatic Islet Treatment and Apoptosis Measurement
Published on: May 2, 2025
531
通过肠道衍生的英多尔3-酸缓解高血糖诱导的莱迪格细胞功能障碍:向细胞亡,内分泌网膜应激反应和类固醇生成
Cyrus Jalili1, Touraj Zamir Nasta1, Fatemeh Makalani2
1Medical Biology of Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Reproductive toxicology (Elmsford, N.Y.)
|July 8, 2025
概括
在高葡萄糖条件下,英多尔-3-酸 (IPA) 改善了莱迪格细胞的功能. 这种肠道化合物增强了细胞活力,促进了激素的产生,并降低了细胞亡和内分泌网膜压力,为糖尿病男性生殖功能障碍提供了潜在的可能性.
科学领域:
- 内分泌学和生殖生物学.
- 代谢障碍 代谢障碍 代谢障碍
- 肠道微生物组研究研究
背景情况:
- 高血糖与男性生殖功能障碍有关,影响莱迪格细胞功能.
- 印-3-酸 (IPA) 是一种来自肠道的代谢物,具有已知的抗糖尿病,抗炎和抗氧化特性.
- 在高血糖条件下IPA对莱迪格细胞的特定作用尚未得到充分证实.
研究的目的:
- 研究IPA对暴露在高血糖环境中的TM3小鼠莱迪格细胞的保护作用.
- 评估IPA对细胞活力,类固醇生成,内质网膜应激和莱迪格细胞的亡的影响.
主要方法:
- TM3莱迪格细胞在低 (5毫米) 和高 (30毫米) 的葡萄糖条件下与不同IPA度 (10和20微米) 进行培养.
- 试验包括MTT检测活力,qRT-PCR检测类固醇基因表达 (Hsd3b1,Fshr,P450scc,Star),Western blot检测内分泌网膜压力标志物 (ATF6,IRE1,GRP78,CHOP),ELISA检测,以及流动细胞计测检测亡.
主要成果:
- 高血糖症显著降低了莱迪格细胞活力,激素生产和类固醇基因表达,同时增加了细胞亡和内质网膜压力标志物.
- IPA治疗,特别是20μM,通过增加细胞活力和类固醇基因表达来抵消高血糖引起的损伤.
- 此外,IPA还减弱了细胞亡,并降低了高血糖的莱迪格细胞中内质网膜压力蛋白 (ATF6,GRP78,CHOP) 的表达.
结论:
- 印-3-酸显示出对高血糖诱导的莱迪格细胞功能障碍的保护作用.
- 通过改善莱迪格细胞功能和减少细胞压力,IPA可以减轻与糖尿病相关的男性生殖并发症.
- IPA成为治疗糖尿病相关男性不孕症的潜在治疗药物.
相关概念视频
Dipeptidyl Peptidase 4 Inhibitors
269
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
269
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
271
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
271
Hypoglycemia and Glucagon
349
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
349
Glucagon-like Receptor Agonists
431
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
431
Oral Hypoglycemic Agents: Biguanides and Glitazones
309
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
309
Hormones Regulating Blood Glucose
4.1K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
4.1K

